AcquisitionOther
Roche acquired 89bio, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Roche -> 89bio, Inc. · $3.5 billion
To acquire pegozafermin for MASH treatment and expand cardiovascular, renal, and metabolism portfolio.
Open source record (SEC) ↗